The Future of Drug-Pricing Transparency

N Engl J Med. 2021 Feb 11;384(6):489-491. doi: 10.1056/NEJMp2033734. Epub 2021 Jan 13.

Authors

William B Feldman¹, Benjamin N Rome¹, Jerry Avorn¹, Aaron S Kesselheim¹

Affiliation

¹ From the Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics (W.B.F., B.N.R., J.A., A.S.K.) and the Division of Pulmonary and Critical Care Medicine (W.B.F.), Department of Medicine, Brigham and Women's Hospital and Harvard Medical School (W.B.F., B.N.R., J.A., A.S.K.) - both in Boston.

PMID: 33440087
DOI: 10.1056/NEJMp2033734

No abstract available

MeSH terms

Advertising / legislation & jurisprudence
Disclosure / legislation & jurisprudence*
Drug Costs / legislation & jurisprudence*
Drug Industry / legislation & jurisprudence*
Humans
Insurance, Pharmaceutical Services
Medicare
Prescription Drugs / economics*
United States

Substances

Prescription Drugs